The pitfalls of CA19-9: Routine testing and comparison of two automated immunoassays in a reference oncology center

American Journal of Clinical Pathology

Volumn 138, Issue 2, 2012, Pages 281-287

  Passerini, Rita ^a   Cassatella, Maria C ^a   Boveri, Sara ^a   Salvatici, Michela ^a   Radice, Davide ^a   Zorzino, Laura ^a   Galli, Claudio ^b   Sandri, Maria T ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b ABBOTT DIAGNOSTICS   (Italy)

Author keywords

Automated immunoassays; CA19 9; Interference; Standardization; Tumor markers

Indexed keywords

CA 19-9 ANTIGEN; MONOCLONAL ANTIBODY;

ANTIGEN DETECTION; ARTICLE; AUTOMATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CHEMILUMINESCENT MICROPARTICLE ENZYME IMMUNOASSAY; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOMETRIUM CANCER; ENZYME IMMUNOASSAY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LABORATORY DEVICE; MAJOR CLINICAL STUDY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; PANCREAS CARCINOMA; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; STOMACH CANCER; UTERUS CANCER;

AGED; CA-19-9 ANTIGEN; CONFIDENCE INTERVALS; DIGESTIVE SYSTEM NEOPLASMS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865403407     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPOPNPLLCYR07H     Document Type: Article

References (38)

1. Magnani JL, Nilsson B, Brockhaus M, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentose II. J Biol Chem. 1982;257:14365-14369. (Pubitemid 13141316)
2. Magnani JL, Steplewski Z, Koprowski H, et al. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983;43:5489-5492. (Pubitemid 14230170)
3. Kannagi R, Fukushi Y, Tachikawa T, et al. Quantitative and qualitative characterization of cancer-associated serum glycoprotein antigens expressing fucosyl or sialosyl-fucosyl type 2 chain polylactosamine. Cancer Res 1986;46:2619-2626. (Pubitemid 16120742)
4. Kannagi R. Carbohydrate antigen sialyl Lewis a: its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med. 2007;30:189-209. (Pubitemid 47235445)
5. Chung YS, Ho JJ, Kim YS, et al. The detection of human pancreatic cancer-associated antigen in the serum of cancer patients. Cancer 1987;60:1636-1643. (Pubitemid 17141020)
6. Victorzon M, Haglund C, Lundin J, et al. A prognostic value of CA 19-9 but not of CEA in patients with gastric cancer. Eur J Surg Oncol. 1995;21:379-384.
7. Gong E, Hirohashi S, Shimosato Y, et al. Expression of carbohydrate antigen 19-9 and stage-specific embryonic antigen 1 in nontumorous and tumorous epithelia of the human colon and rectum. J Natl Cancer Inst 1995;75:447-454.
8. Berthiot G, Marechal F, Cattan A, et al. Serum levels of CA-50, CA-19.9, CA-125, neuron specific enolase and carcinoembryonic antigen in lung cancer and benign diseases of the lung. Biomed Pharmacother. 1989;43:613-620. (Pubitemid 20077688)
9. Loy TS, Sharp SC, Andershock CJ, et al. Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas: an immunohistochemical study of 527 cases. Am J Clin Pathol. 1993;99:726-728. (Pubitemid 23181823)
10. Podczaski E, Kaminski P, Hackett T, et al. Tissue CA 125 and CA 19-9 in malignant, mixed mesodermal tumors of the uterus. Gynecol Oncol. 1993;49:56-60. (Pubitemid 23148583)
11. Borras G, Molina R, Xercavins J, et al. Tumor antigens CA19.9, CA125, and CEA in carcinoma of the uterine cervix. Gynecol Oncol 1995;57:205-211.
12. Molina L, Ojeda B, Filella X, et al. A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas. Tumour Biol 1992;13:278-286. (Pubitemid 23053361)
13. Passerini R, Riggio D, Salvatici M, et al. Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update. Clin Chem Lab Med. 2007;45:100-104. (Pubitemid 46155569)
14. Birk B, Henne V, Hipp B, et al. Cobas Core CA 19-9 II EIA: new CA 19-9 enzyme immunoassay with high correlation to radioimmunoassays. Anticancer Res. 1997;17:2911-2914. (Pubitemid 27434818)
15. Duffy MG, Sturgeon C, Lamerz R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21:441-447.
16. Goonnetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33:266-270. (Pubitemid 46488663)
17. Osswald BR, Klee FE, Wysocki S. The reliability of highly elevated CA 19-9 levels. Dis Markers. 1993;11:275-278. (Pubitemid 24171604)
18. Ventrucci M, Pozzato P, Cipolla A, et al. Persistent elevation of serum CA 19-9 with no evidence of malignant disease. Dig Liver Dis. 2009;4:357-363.
19. Kim BJ, Lee KT, Moon TG, et al. How do we interpret an elevated carbohydrated antigen CA 19-9 level in asymptomatic subjects? Dig Liver Dis. 2009;41:364-369.
20. Walker PLC, Crook M. Tumor marker requesting in primary care and the role of the laboratory. Am J Clin Pathol 2011;64:443-446.
21. Buenger S, Laubert T, Roblick UJ, et al. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol. 2011;137:375-389.
22. Vestergaard EM, Hein HO, Meyer H, et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem. 1999;45:54-61. (Pubitemid 29036385)
23. Plebani M, Giacomini A, Beghi L, et al. Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation. Anticancer Res. 1996;16:2249-2252. (Pubitemid 26265573)
24. Erden G, Barazi AO, Tezcan G, et al. Biological variation and reference change values of CA 19-9, CEA, AFP in serum of healthy individuals. Scand J Clin Lab Invest 2007;68:212-218. (Pubitemid 351630827)
25. Steinberg W.The clinical utility of the CA 19-9 tumor associate antigen. Am J Gastroenterol 1990;85:350-355. (Pubitemid 20140602)
26. Sturgeon CM, Duffy MJ, Hofmann BR, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010;56:e1-e48.
27. Takahashi Y, Takeuchi T, Sakamoto J, et al. The usefulness of CEA and/or CA 19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6:142-145. (Pubitemid 37221564)
28. Choi SR, Jang JS, Lee JH, et al. Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci 2006;51:2081-2086. (Pubitemid 44832595)
29. Kim HJ, Lee K-W, Kim YJ, et al. Chemotherapy-induced transient CEA and CA 19-9 surges in patients with metastatic or recurrent gastric cancer. Acta Oncologica. 2009;48:395-390.
30. Kawamura YJ, Tokumitsu A, Mizokami K, et al. First alert for recurrence during follow-up after potentially curative resection for colorectal carcinoma: CA 19-9 should be included in surveillance programs. Clin Colorectal Cancer. 2010;9:48-51.
31. de Haas RJ, Wicherts DA, Flores E, et al. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol 2010;17:1010-1023.
32. Kelly PJ, Archbold P, Price JH, et al. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol 2010;63:169-173.
33. La'ulu SL, Roberts WL. Performance characteristics of five automated CA 19-9 assays. Am J Clin Pathol. 2007;127:436-440. (Pubitemid 46806338)
34. Hotakainen K, Tanner P, Alfthan H, et al. Comparison of three immunoassays for CA 19-9. Clin Chim Acta. 2009;400:123-127.
35. Deinzer M, Faissner R, Metzger T, et al. Comparison of two different methods for CA19-9 antigen determination. Clin Lab. 2010;56:319-325.
36. Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem. 1999;45:942-956. (Pubitemid 29340529)
37. Berth M, Bosmans E, Everaert J, et al. Rheumatoid factor interference in the determination of carbohydrate antigen 19-9 (CA 19-9). Clin Chem Lab Med. 2006;44:1137-1139. (Pubitemid 44370937)
38. Liang Y, Yang Z, Ye W, et al. Falsely elevated carbohydrate antigen 19-9 level due to heterophilic antibody interference but not rheumatoid factor: a case report. Clin Chem Lab Med. 2009;47:116-117.